Cost analysis of extended half-life recombinant factor IX products in the treatment of haemophilia B in Italy: an update
{{output}}
Haemophilia B (HB) is a rare disease which may lead to chronic disabling arthropathy, resulting in a significant clinical, social and economic impact. In recent years, new extended half-life (EHL) factor IX concentrates produced by recombinant technology (rFIX... ...
